Stockhub

Brii Biosciences Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 September 2022

  • curprev 22:4522:45, 21 September 2022 95.149.241.133 talk 1,129 bytes +1,129 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic..."
Retrieved from "https://stockhub.co/research/Brii_Biosciences_Limited"